• EN/ES

    Orthopedics

    WebHealthNetwork : 2,378,479


  • Benefits & Savings

  • : Hyperplasia

Hyperplasia - 135 Studies Found

Completed : Three Drug Combination Therapy Versus Conventional Treatment of Children With Congenital Adrenal Hyperplasia
:
  • Congenital Adrenal Hyperplasia
  • Growth Disorder

: 1999-11-03
:
  • Drug: Flutamide and Testolactone
  • Drug: Des

Completed : Prenatal Dex Study
: Congenital Adrenal Hyperplasia
: 2016-05-25
: Behavioral: Neuropsychological and cognitive assessment
Completed : Congenital Adrenal Hyperplasia: Calcium Channels as Therapeutic Targets
: Congenital Adrenal Hyperplasia
: 1999-11-03
: Drug: Nifedipine
Completed : A Study of the Efficacy, Safety and Tolerability of Chronocort in Treating CAH
: Congenital Adrenal Hyperplasia
: 2016-08-22
: Drug: Hydrocortisone Modified release hydrocortisone
Completed : Comparison of Two Forms of Hydrocortisone in Patients With Congenital Adrenal Hyperplasia
:
  • Congenital Adrenal Hyperplasia
  • 21-Hydroxy
    : 2007-08-22
    :
    • Drug: Chronocort Chronocort 30

Completed : Comparison of Cortisol Pump With Standard Treatment for Congenital Adrenal Hyperplasia
:
  • Adrenal Insufficiency
  • Excess Androgen
  • Congenital : 2013-05-17
    :
    • Drug: Hydrocortisone (Solucortef)
    • Device:

Active, not recruiting : A Study to Evaluate the Safety of Long-term Treatment With Siltuximab in Patients With Multicentric Castleman's Disease
: Multicentric Castleman's Disease
: 2011-04-21
: Drug: Siltuximab Type=exact number, unit=mg/kg, number=11, form=intravenous solution, route=intravenous.
Completed : A Study to Provide RoActemra/Actemra (Tocilzumab) to Patients With Multicentric Castleman's Disease Who Demonstrated Benefit From Previous RoActemra/Actemra Treatment
: Castleman's Disease
: 2010-08-13
: Drug: tocilizumab [RoActemra/Actemra] maintenance dose
Active, not recruiting : A Study to Evaluate the Efficacy and Safety of CNTO328 Plus Best Supportive Care in Multicentric Castleman's Disease
: Multicentric Castleman's Disease
: 2009-11-30
:
  • Drug: Siltuximab Siltuximab 11

Withdrawn : Valganciclovir to Treat HHV-8 Associated Multicentric Castleman's Disease
: Giant Lymph Node Hyperplasia
: 2006-08-08
: Drug: Valganciclovir valganciclovir open label, two 450mg tablets orally, twice a day
<<< Previous | Next >>>
Orthopedics Health
Orthopedics Health WebHealth Network Media
  • WebHealthNetwork
  • DiabetesHealthMatters
  • HeartandStrokeHealth
  • WomensHealthCareCommunity
  • AsthmaHealthCenter
  • CancerHealthCenter
  • MentalHealthHelpCenter
  • Skincarehealthcenter
  • DigestiveTractHealth
  • VaccineHealthCenter
  • PainHealthCenter
  • FightingAddictionCenter
  • ObesityHealthMatters
  • SeniorHealthcareMatters
  • BrainAndNerveCenter
  • PediatricsHealthCenter
  • RareDiseasesHealthCenter
  • Wealth Mason
  • Home Owners Circle
  • EasyInsuranceFinder
  • EduJumpStart
  • SaleSpider
  • ScoopCafe
  • SaleSpiderMedia
  • Viewpoint.World
  • TravelerBooked
  • TechNewsBytes
  • Contact Us
  • Advertising Privacy Policy

This site uses cookies for analytics and advertising. No personal information is collected.

© Orthopedics Health .

We use cookies to enhance your experience, analyze anonymized traffic, and deliver personalized content and ads. No personal information is collected. By using our website, you consent to our use of cookies and agree to our data practices as described in our Privacy Policy. To Reject, please change your browser settings.